BeNeLuxBelgiumNetherlandsLuxembourg

European geneticists call for ban on DNA patents

20.05.2008

Brussels – To ensure that new genetic tests become available to patients, European human geneticists have called for a ban on patents covering disease genes and related SNPs. Additionally, the group under Prof. Gert Matthijs (Univ. Leuven, Belgium) from the European Society of Human Genetics (ESHG) recommended that EU policymakers should establish binding guidelines for licensing patented DNA, RNA and cDNA sequences to prevent licensors from acquiring “exclusive control over human genetic information”. At the end of April, the scientists issued a broad set of recommendations focused on reshaping EU patenting law to prevent monopolies that hamper the development of innovative genetic tests (Eur. J. Human Gen. 16, 405-411). The geneticists now want to lobby for these claims at the Patent Office, the European Parliament and the European Commission in order to stimulate the incorporation of the recommendations into existing patent legislation.

Multiplex-tests will require costly licenses

The move is driven by the fact that phenotype-based testing, which looks at a huge set of DNA sequences simultaneously, will become widespread in the near future, and would require multiple and costly licences. Overly-broad patents that cover cDNA sequences and the proteins encoded by them could hamper innovation, according to the 23 authors of the recommendations. “As soon as the first monopolies on genetic tests started appearing, we realised patenting had become a major issue,” said Matthijs.
The chair of the group, who has been involved in drafting the guidelines since 2005, hopes that its publication will also have a major impact on the US, where patenting genes was practiced extensively in the course of the Human Genome Project. Patenting of DNA sequences has become difficult since then, however, because the number of relevant genes is limited. Additionally, market exclusivity is a prerequisite for the huge investment needed to develop human therapeutics and diagnostics. Regulators will therefore have to strike a balance between the needs of innovative biopharmaceutical companies and researchers.

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/european-geneticists-call-for-ban-on-dna-patents.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR27.2%
  • MOLOGEN7.65 EUR3.4%
  • HBM85.50 CHF3.1%

FLOP

  • PAION2.20 EUR-32.3%
  • 4SC0.80 EUR-29.8%
  • CYTOS0.16 CHF-23.8%

TOP

  • SANTHERA81.90 CHF2267.1%
  • CO.DON2.69 EUR195.6%
  • PAION2.20 EUR155.8%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014


Current issue

All issues

Product of the week

Products